Australia is projected to face a $90 billion annual obesity crisis by 2032 while currently spending below the OECD average on preventative health measures. A report by Novo Nordisk, prepared by the McKell Institute and the Menzies Research Centre, reveals that obesity already costs the nation approximately $39 billion annually, accounting for 2% of GDP. The report advocates for a multifaceted policy approach, including phased subsidies for GLP-1 medications such as Ozempic and Wegovy, aimed at high-risk and disadvantaged groups to alleviate financial pressures on the healthcare system. The federal health minister is considering expanding access to these medications, which are already subsidized for type 2 diabetes treatment. It also suggests enhancing nutrition, exercise, and behavioral support for those qualifying for government-subsidized drugs and increasing preventative health spending to align with OECD standards.
Why It Matters
About 67% of Australian adults are classified as overweight or obese, a rise from 56% in 1995, while one-in-four children face similar weight issues, with a high likelihood of continuing into adulthood. Obesity disproportionately affects low-income individuals and those in regional areas, exacerbating health inequalities. The growing prevalence of obesity has significant implications for Australia’s economy and healthcare system, highlighting the urgent need for effective interventions and policies. Increased investment in preventative health could help mitigate the long-term costs associated with obesity-related health issues and improve overall public health outcomes.
Want More Context? 🔎
